Notes & TipsMeningococcal X polysaccharide quantification by high-performance anion-exchange chromatography using synthetic N-acetylglucosamine-4-phosphate as standard
Section snippets
Acknowledgments
We thank Gerd Pluschke of the Swiss Tropical Institute (Basel, Switzerland), who kindly provided the Neisseria meningitidis X5967 strain (ST 750) used for MenX polysaccharide production by bacterial growth.
References (17)
- et al.
Global epidemiology of meningococcal disease
Vaccine
(2009) - et al.
Relative stability of meningococcal serogroup A and X polysaccharides
Vaccine
(2012) - et al.
Determination of the structure and conformation of bacterial polysaccharides by carbon 13 nuclear magnetic resonance: studies on the group-specific antigens of Neisseria meningitidis serogroups A and X
J. Biol. Chem.
(1974) - et al.
Characterization of size, structure, and purity of serogroup X Neisseria meningitidis polysaccharide, and development of an assay for quantification of human antibodies
Vaccine
(2012) - et al.
Quantitative proton nuclear magnetic resonance evaluation and total assignment of the capsular polysaccharide Neisseria meningitidis serogroup X
J. Pharm. Biomed. Anal.
(2012) - et al.
Simultaneous determination of glucosamine and glucosamine 4-phosphate in lipid A with high-performance anion-exchange chromatography (HPAEC)
Carbohydr. Res.
(1998) - et al.
Prevalence of meningococcal serogroups and description of three new groups
Am. J. Epidemiol.
(1968) - et al.
Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger
Am. J. Trop. Med. Hyg.
(2009)
There are more references available in the full text version of this article.
Cited by (11)
Method development and validation of unbound saccharide content (serogroup A, C, Y, W, X) in novel pentavalent meningococcal polysaccharide conjugate vaccine with two different carrier proteins
2023, Journal of Pharmaceutical and Biomedical AnalysisQuantitation of novel pentavalent meningococcal polysaccharide conjugate vaccine (Men A-TT, Men C-CRM, Men Y-CRM, Men W-CRM, Men X-TT) using sandwich ELISA
2020, VaccineCitation Excerpt :Available meningococcal vaccines are unable to provide protection against serogroup X [17] and currently no vaccine is available in the market against Men X [18]. However, recent development of a glycoconjugate vaccine against Men X has been reported [11,16]. World Health Organization’s increasing interest towards inclusion of serogroup X as one of the causative agents for epidemic meningitis [19], has raised a challenge for vaccine industry to develop efficient vaccine against Men X.
Potential targets for next generation antimicrobial glycoconjugate vaccines
2018, FEMS Microbiology Reviews
Copyright © 2013 Elsevier Inc. All rights reserved.